If a seller wants to explain that he is selling because he thinks a third injected monoclonal antibody prophylaxis is approved is material to Enanta's prospects, and that this wasn't expected after two successful phase 3 trials by a major pharma, that's useful information. If you disagree, add it to your scales when weighing whether to add or establish a position, seems like it's always useful to have a sense of why people are selling. I added a few shares.
Market Data 
Markets 
AI
